Latest News & Features
Refine Search
Americas
The status of patentability for new dosage regimes in Mexico is unclear, but there have been some positive signs, says Pablo Fuentes. 1 May 2012
Biotechnology
The Supreme Court’s much-anticipated Prometheus decision has prompted strong reactions among IP practitioners, as MaryAnne Armstrong, PhD, explains. 1 January 2012
Big Pharma
Advocate-General Verica Trstenjak has delivered an opinion in the case of Neurim Pharmaceuticals that, if followed by the Court of Justice of the EU, will profoundly liberalise the law governing SPCs in Europe. 1 January 2012
Big Pharma
When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne. 1 January 2012
Biotechnology
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of
IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs. 1 January 2012
Biotechnology
The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes. 1 January 2012
Biotechnology
The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important. 1 January 2012
Asia-Pacific
An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains. 1 May 2011
Big Pharma
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions. 1 May 2011
Biotechnology
A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains. 1 May 2011

